With the 2019 breakthrough in the development of highly effective modulator therapy
providing unprecedented clinical benefits for over 90% of patients with cystic fibrosis who …

Cystic fibrosis transmembrane conductance regulator (CFTR) is an ion transporter that
regulates mucus hydration, viscosity and acidity of the airway epithelial surface. Genetic …

Standard follow-up and symptomatic treatment have allowed most patients with cystic
fibrosis to live to young adulthood. However, many patients still die prematurely from …

Cystic fibrosis (CF) remains the most common life-shortening hereditary disease in white
populations, with high morbidity and mortality related to chronic airway mucus obstruction …

Cystic fibrosis (CF) is caused by mutations in the gene encoding the cystic fibrosis
transmembrane conductance regulator (CFTR), an anion channel expressed in epithelial …

An improved understanding of the cystic fibrosis (CF) transmembrane conductance regulator
(CFTR) protein structure and the consequences of CFTR gene mutations have allowed the …

Cystic fibrosis is caused by dysfunction or deficiency of the cystic fibrosis transmembrane
conductance regulator (CFTR) protein, an epithelial chloride channel that has a key role in …

The advent of Cystic fibrosis transmembrane receptor (CFTR) modulators in 2012 was a
critical event in the history of cystic fibrosis (CF) treatment. Unlike traditional therapies that …

Mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene cause
the life-limiting hereditary disease, cystic fibrosis (CF). Decreased or absent functional CFTR …

Treatment for cystic fibrosis (CF) has conventionally targeted downstream consequences of
the defect such as mucus plugging and infection. More recently, significant advances have …